Peptic ulcers are open sores that develop on the inner lining of the stomach, upper small intestine, or esophagus due to the erosion of the protective mucous layer by gastric acids or a Helicobacter pylori infection. The lifetime prevalence of peptic ulcer disease (PUD) is approximately 5%-10%, with an annual incidence of 0.1%-0.3%. The growth in the drug pipeline is driven by the rising incidence of peptic ulcers, advancements in peptic ulcers drug development, and an increasing focus on combination therapies. Potassium-competitive acid blockers (P-CAB) are actively being used for the treatment. The peptic ulcers pipeline analysis by Expert Market Research highlights ongoing research into innovative therapeutics, such as next-generation proton pump inhibitors and gastroprotective agents, aimed at improving efficacy and patient outcomes.
Major companies involved in the peptic ulcers pipeline analysis include Il-Yang Pharm. Co., Ltd., Onconic Therapeutics Inc., and others.
Leading drugs currently in the pipeline include Misoprostol Oral Tablet, Ilaprazole, Vonorasan Fumarate Injection, and others.
The peptic ulcer pipeline is expanding due to the rising prevalence of Helicobacter pylori infections, advancements in proton pump inhibitors, and the development of novel therapeutics like potassium-competitive acid blockers.
The Peptic Ulcers Pipeline Analysis Report by Expert Market Research gives comprehensive insights into peptic ulcers therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for Peptic Ulcers. The peptic ulcers report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The peptic ulcers pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition and alignment with peptic ulcers treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to peptic ulcers.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Peptic ulcers are open sores that develop on the inner lining of the stomach or the upper part of the small intestine. They occur when the protective mucous layer is eroded by stomach acid, often due to Helicobacter pylori infection or prolonged use of nonsteroidal anti-inflammatory drugs (NSAIDs). This erosion leads to symptoms like abdominal pain, bloating, and nausea.
Peptic ulcers are treated by eliminating H. pylori infections with a combination of antibiotics and proton pump inhibitors (PPIs), reducing stomach acid with PPIs or histamine (H2) blockers, and protecting the stomach lining with medications like sucralfate. Discontinuing or modifying NSAID use is also recommended when applicable. Lifestyle changes, such as stress management and avoiding irritants like alcohol and smoking, support healing and prevent recurrence. A 2024 review published in JAMA emphasized the importance of eradicating H. pylori to reduce recurrence rates and recommended acid-blocking treatments like proton pump inhibitors as the primary therapy.
The peptic ulcer disease (PUD) pipeline focuses on innovative treatments to address increasing cases worldwide. The lifelong prevalence in Western countries is 5% to 10%, with an annual incidence of 0.1% to 0.3%. In the United States, PUD affects 1% of the population, leading to around 54,000 hospital admissions annually for bleeding ulcers. Advancements in drug development aim to improve treatment efficacy and patient outcomes.
This section of the report covers the analysis of peptic ulcers drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase IV covers a major share of the total peptic ulcers clinical trials. Phase IV, comprising around 52% of the clinical trials, is driving post-marketing research and safety assessments. Phase III, with 24%, focuses on large-scale efficacy trials, ensuring treatment effectiveness, while Phase II has approximately 20%. Advancements in later phases strengthen market growth, improving patient outcomes and treatment accessibility.
The drug molecule categories covered under the peptic ulcers pipeline analysis include small molecules, fusion proteins, monoclonal antibodies, peptides, gene therapies, and others. The peptic ulcers report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for peptic ulcers.
Antibiotics play a crucial role in treating peptic ulcers caused by Helicobacter pylori infection. A combination therapy with two or three antibiotics, such as amoxicillin, clarithromycin, metronidazole, or tetracycline, alongside a proton pump inhibitor, is commonly prescribed. This approach effectively eradicates the infection, promotes ulcer healing, and reduces the risk of recurrence, particularly in duodenal ulcers.
The EMR report for the peptic ulcers pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed peptic ulcers therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in peptic ulcers clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for peptic ulcers. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of peptic ulcers drug candidates.
Misoprostol is currently being evaluated in a Phase IV clinical trial sponsored by the Chinese University of Hong Kong. This study aims to assess whether combining misoprostol with lansoprazole is more effective than lansoprazole alone in preventing recurrent bleeding in patients with a history of idiopathic gastroduodenal ulcers. Misoprostol is a synthetic prostaglandin E1 analog approved for preventing and treating gastric ulcers induced by nonsteroidal anti-inflammatory drugs (NSAIDs). It works by protecting the gastrointestinal mucosa and reducing stomach acid secretion.
Ilaprazole, a novel proton pump inhibitor developed by Il-Yang Pharm. Co., Ltd., is currently undergoing a Phase III clinical trial to evaluate its efficacy and safety in preventing NSAID-associated peptic ulcers. The drug is extensively metabolized to ilaprazole sulfone, primarily by the CYP3A enzyme. The study aims to demonstrate Ilaprazole's non-inferiority to an active control by evaluating the proportion of subjects developing peptic ulcers over 24 weeks.
Vonorasan fumarate injection, sponsored by Shandong New Time Pharmaceutical Co., Ltd., is in a Phase II clinical trial for peptic ulcer bleeding. Vonoprazan is a novel potassium-competitive acid blocker (P-CAB) that inhibits gastric acid secretion by reversibly blocking potassium binding to gastric H+/K+ ATPase. This mechanism allows for rapid and potent acid suppression, with a prolonged duration of action compared to traditional proton pump inhibitors (PPIs).
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Peptic Ulcers Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for peptic ulcers. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within peptic ulcers pipeline insights.
Upto 35% Off
USD
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share